Rhythm Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Rhythm Pharmaceuticals, Inc.
Bristol Myers Squibb's lisocabtagene maraleucel, UCB's bimekizumab and Rhythm Pharmaceuticals' setmelanotide are among the six latest additions to the list of products under review at the European Medicines Agency.
Two products that were under fast-track review at the European Medicines Agency have reverted to standard review timelines – Eiger's lonafarnib and GSK's dostarlimab. The Pink Sheet tracker logs these and other developments relating to the agency's accelerated assessment mechanism.
Potential treatments from BeiGene, AstraZeneca, Bayer and Cancer Prevention Pharmaceuticals are under review at the European Medicines Agency.
With goal dates for almost 40 novel drugs and biologics coming up in the second half of 2020 after a record number of first half approvals, even the pandemic looks unlikely to prevent another solid year for innovative drugs at US FDA.
- Large Molecule
- Other Names / Subsidiaries
- Rhythm Metabolic, Inc.